CoronaVac® generates good immune memory after the second dose. Third dose of CoronaVac® induces strong immune response. No serious adverse reactions reported
The state registry notes that the trials will last until late 2026 and will involve 360 patients. The vaccine will be administered via an intramuscular injection.
AI and big data have been identified by healthcare industry professionals as the top technologies that will transform pharmaceutical drug discovery and development processes.
The Horizon Europe program is part of broader steps the EU has taken to combat the pandemic and is congruent with the broader goals of the HERA incubator.